Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Top Cited Papers
- 9 October 2009
- journal article
- other
- Published byĀ American Association for the Advancement of Science (AAAS)Ā inĀ Science
- Vol.Ā 326 Ā (5950) , 285-289
- https://doi.org/10.1126/science.1178746
Abstract
Anti-HIV Antibodies: One of the top priorities for an HIV vaccine is the ability to elicit a broadly neutralizing antibody response, which should provide the best protection against infection. In the 25 years since the discovery of HIV, very few broadly neutralizing antibodies have been identified, and those that do exist were discovered nearly two decades ago. Using a high-throughput culture system, Walker et al. (p. 285 ; published online 3 September) now identify two additional broadly neutralizing antibodies isolated from a clade A HIV-infected African donor. These antibodies exhibit great potency and, in contrast to other known broadly neutralizing antibodies, are able to neutralize a wide range of viruses from many different clades. The antibodies recognize a motif in the trimerized viral envelope protein that is found in conserved regions of the variable loops of the gp120 subunit. Identification of this motif provides an intriguing new target for vaccine development.Keywords
This publication has 25 references indexed in Scilit:
- Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection AlgorithmJournal of Virology, 2009
- Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing TitersPLoS Pathogens, 2009
- The Human Immunodeficiency Virus Type 1 Envelope Spike of Primary Viruses Can Suppress Antibody Access to Variable RegionsJournal of Virology, 2009
- Challenges in the development of an HIV-1 vaccineNature, 2008
- Toward an AIDS VaccineScience, 2008
- The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine DesignMicrobiology and Molecular Biology Reviews, 2008
- An HIV Vaccine ā Evolving ConceptsNew England Journal of Medicine, 2007
- Type-Specific Epitopes Targeted by Monoclonal Antibodies with Exceptionally Potent Neutralizing Activities for Selected Strains of Human Immunodeficiency Virus Type 1 Map to a Common Region of the V2 Domain of gp120 and Differ Only at Single Positions from the Clade B Consensus SequenceJournal of Virology, 2007
- The C108g Epitope in the V2 Domain of gp120 Functions as a Potent Neutralization Target When Introduced into Envelope Proteins Derived from Human Immunodeficiency Virus Type 1 Primary IsolatesJournal of Virology, 2005
- Crystal Structure of the Broadly Cross-Reactive HIV-1-Neutralizing Fab X5 and Fine Mapping of Its Epitope,Biochemistry, 2004